InspireMD Reports First Quarter 2026 Financial Results

InspireMD reported a total revenue of $3.4 million for Q1 2026, marking a 122% increase from the same period last year. The company has recently received FDA approval to start the CGUARDIANS III clinical trial for its neuro protection system, and anticipates further FDA approvals in 2026 that could expand its market. Despite a voluntary pause in the commercialization of one of its products, the company is implementing enhancements to improve technical performance and expedite adoption.